Dr. Amengual's research focus is on the development of novel drugs designed to epigenetically target signaling pathways of B-cell lymphoma. Specifically, Dr. Amengual is working on modulating the Bcl6 : p53 Axis in germinal-center type diffuse large B-cell lymphoma with histone deacetylase inhibitors (HDACi's) and sirtuin inhibitors to modulate the functional status of this oncogene and tumor suppressor protein. She is also evaluating the effects of a first-in-class selective HDAC6 inhibitor's impact on activating the unfolded protein response and ultimately leading to apoptosis in lymphoma. Dr. Amengual brings extensive laboratory experience studying targeted therapy in the preclinical setting and translating her findings directly to patient care.